Ispire's Stock Trading Volume Decreases 51% on November 5th

Business by 2FIRSTS.ai
Dec.06.2023
Ispire's Stock Trading Volume Decreases 51% on November 5th
Ispire (ISPR) stock trades strong with a volume of 35,318 shares, down 51% from the previous day.

According to a report by Rivertonroll on December 5th, the trading volume of Ispire (Ispire Technology Inc., Nasdaq stock code: ISPR) was strong on November 5th. During the trading period, a total of 35,318 shares were traded, a decrease of 51% compared to the previous trading day's volume of 72,489 shares. The stock ended at a trading price of $9.92, up from the previous closing price of $9.85.

 

The stock's 50-day simple moving average is $9.79, while its 200-day simple moving average is $9.28.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Heno Biotech Releases 2024 ESG Report at Inter Tabac, Setting a New Global Benchmark for the Nicotine Industry Through Green Development and Compliance Governance
Heno Biotech Releases 2024 ESG Report at Inter Tabac, Setting a New Global Benchmark for the Nicotine Industry Through Green Development and Compliance Governance
At InterTabac, the world’s largest tobacco industry exhibition in Dortmund, Germany, Heno Biotech released its 2024 Environmental, Social, and Governance (ESG) Report. As a leading enterprise in China’s natural nicotine sector, Heno presented its third consecutive annual ESG disclosure, highlighting achievements in green development, compliance governance, and social responsibility, setting a new benchmark for sustainable growth in the industry.
Sep.18
London police crackdown on drug-laced e-cigarettes: Over 2,000 poisoning charges expected in 2024-2025
London police crackdown on drug-laced e-cigarettes: Over 2,000 poisoning charges expected in 2024-2025
London police announced a crackdown on drug-tainted e-cigarettes. The operation stemmed from an incident in the southeast of the capital where e-cigarettes were laced with "cannabis-like products," leading to the hospitalization of a 14-year-old. Data shows that between March 2024 and March 2025, London police received over 2,000 allegations of drug-tainted e-cigarettes. Of the victims in August 2025, 66% were women, a disproportionately high proportion.
Sep.26 by 2FIRSTS.ai
Malaysia's Health Minister: Plans to ban the sale of e-cigarettes by mid-2026, starting with open-cell products
Malaysia's Health Minister: Plans to ban the sale of e-cigarettes by mid-2026, starting with open-cell products
Malaysia plans to ban and phase out all e-cigarette sales nationwide by mid-2026, pending cabinet approval.
Sep.26 by 2FIRSTS.ai
SKE’s Parent Company Yinghe Technology Reports 80% Drop in Q3 Net Profit, Revenue Up 22.85% Year-on-Year
SKE’s Parent Company Yinghe Technology Reports 80% Drop in Q3 Net Profit, Revenue Up 22.85% Year-on-Year
Yinghe Technology (SZ: 300457), parent company of SKE, saw Q3 net profit plunge 80.3% to 31.06 million yuan, while revenue rose 22.85% to 2.52 billion yuan. The decline was mainly driven by higher costs and expenses.
Oct.28 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
ZYN’s Trademark Dilemma in China | Legal Opinion Submitted to 2Firsts
ZYN’s Trademark Dilemma in China | Legal Opinion Submitted to 2Firsts
ZYN faces trademark revocation and enforcement challenges in China. In this legal commentary submitted to 2Firsts, the author examines regulatory gaps, enforcement hurdles, and the high legal risks surrounding nicotine pouch trademarks.
Oct.14